These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 8119326

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol O-methyltransferase.
    Törnwall M, Tuomainen P, Männistö PT.
    Eur J Pharmacol; 1993 Aug 03; 239(1-3):39-45. PubMed ID: 8223912
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
    Gerlach M, Xiao AY, Kuhn W, Lehnfeld R, Waldmeier P, Sontag KH, Riederer P.
    J Neural Transm (Vienna); 2001 Aug 03; 108(2):189-204. PubMed ID: 11314772
    [Abstract] [Full Text] [Related]

  • 7. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.
    Kaakkola S, Gordin A, Männistö PT.
    Gen Pharmacol; 1994 Sep 03; 25(5):813-24. PubMed ID: 7835624
    [Abstract] [Full Text] [Related]

  • 8. Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum.
    Kaakkola S, Wurtman RJ.
    J Neurochem; 1993 Jan 03; 60(1):137-44. PubMed ID: 8417137
    [Abstract] [Full Text] [Related]

  • 9. Catechol O-methyltransferase: characterization of the protein, its gene, and the preclinical pharmacology of COMT inhibitors.
    Männistö PT.
    Adv Pharmacol; 1998 Jan 03; 42():324-8. PubMed ID: 9327906
    [No Abstract] [Full Text] [Related]

  • 10. Neurochemical and psychomotor interactions of new selective COMT inhibitors with clorgyline and nomifensine in levodopa-treated rats and mice.
    Törnwall M, Tuomainen P, Männistö PT.
    Arch Int Pharmacodyn Ther; 1992 Jan 03; 320():5-20. PubMed ID: 1300941
    [Abstract] [Full Text] [Related]

  • 11. Different modes of action of catecholamine-O-methyltransferase inhibitors entacapone and tolcapone on adenylyl cyclase activity in vitro.
    Gerlach M, Ukai W, Ozawa H, Riederer P.
    J Neural Transm (Vienna); 2002 May 03; 109(5-6):789-95. PubMed ID: 12111468
    [Abstract] [Full Text] [Related]

  • 12. No change of brain extracellular catecholamine levels after acute catechol-O-methyltransferase inhibition: a microdialysis study in anaesthetized rats.
    Li YH, Wirth T, Huotari M, Laitinen K, MacDonald E, Männistö PT.
    Eur J Pharmacol; 1998 Sep 04; 356(2-3):127-37. PubMed ID: 9774242
    [Abstract] [Full Text] [Related]

  • 13. Positron emission tomography in drug evaluation: influence of three different catechol-O-methyltransferase inhibitors on metabolism of [NCA] 6-[18F]fluoro-L-dopa in rhesus monkey.
    Günther I, Psylla M, Reddy GN, Antonini A, Vontobel P, Reist HW, Zollinger A, Nickles RJ, Beer HF, Schubiger PA.
    Nucl Med Biol; 1995 Oct 04; 22(7):921-7. PubMed ID: 8547890
    [Abstract] [Full Text] [Related]

  • 14. Effects of entacapone and tolcapone on mitochondrial membrane potential.
    Haasio K, Koponen A, Penttilä KE, Nissinen E.
    Eur J Pharmacol; 2002 Oct 18; 453(1):21-6. PubMed ID: 12393055
    [Abstract] [Full Text] [Related]

  • 15. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.
    Napolitano A, Bellini G, Borroni E, Zürcher G, Bonuccelli U.
    Parkinsonism Relat Disord; 2003 Jan 18; 9(3):145-50. PubMed ID: 12573869
    [Abstract] [Full Text] [Related]

  • 16. Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement.
    Tohgi H, Abe T, Yamazaki K, Saheki M, Takahashi S, Tsukamoto Y.
    Neurosci Lett; 1995 Jun 16; 192(3):165-8. PubMed ID: 7566641
    [Abstract] [Full Text] [Related]

  • 17. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.
    Napolitano A, Zürcher G, Da Prada M.
    Eur J Pharmacol; 1995 Feb 06; 273(3):215-21. PubMed ID: 7737328
    [Abstract] [Full Text] [Related]

  • 18. Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA.
    Doudet DJ, Chan GL, Holden JE, Pate BD, Morrison KS, Calne DB, Ruth TJ.
    Eur J Pharmacol; 1997 Sep 03; 334(1):31-8. PubMed ID: 9346324
    [Abstract] [Full Text] [Related]

  • 19. Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease.
    Waters C.
    J Am Geriatr Soc; 2000 Jun 03; 48(6):692-8. PubMed ID: 10855610
    [Abstract] [Full Text] [Related]

  • 20. COMT inhibition: a new treatment strategy for Parkinson's disease.
    Kurth MC, Adler CH.
    Neurology; 1998 May 03; 50(5 Suppl 5):S3-14. PubMed ID: 9591516
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.